CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer-Reference-Cited by-同舟云学术

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

Published:2007-12 Issue:6 Volume:9 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Esteva Francisco J,Wang Jing,Lin Feng,Mejia Jaime A,Yan Kai,Altundag Kadri,Valero Vicente,Buzdar Aman U,Hortobagyi Gabriel N,Symmans W Fraser,Pusztai Lajos

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/article/10.1186/bcr1836/fulltext.html

Reference38 articles.

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182. 10.1126/science.3798106.

2. Esteva FJ, Hortobagi GN: Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004, 6: 109-118. 10.1186/bcr777.

3. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002, 20: 3095-3105.

4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.

5. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005, 23: 4265-4274. 10.1200/JCO.2005.04.173.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies;JCO Oncology Practice;2024-08

2. Prolactin-induced protein (PIP) increases the sensitivity of breast cancer cells to drug-induced apoptosis;Scientific Reports;2023-04-21

3. High Expression of TIMM17B Is a Potential Diagnostic and Prognostic Marker of Breast Cancer;Cellular and Molecular Biology;2023-03-31

4. Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer;Medical Science Monitor;2020-06-20

5. Transcriptional splice variants of CD40 and its prognostic value in breast cancer;TURKISH JOURNAL OF BIOLOGY;2020-04-02